Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Recent Trends in GLP-1 Use and Spending in Medicare Ahead of the Trump administrations planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicares negotiated price for certain GLP-1 products beginning in 2027, new data from the Centers for Medicare & Medicaid Services (CMS) shows that use and spending for these drugs under Medicare has grown substantially in recent years, reflecting their demonstrated effectiveness at treating type 2 diabetes and other conditions
The supporting literature fills in the pharmacology
Glucose-dependent insulin secretion & metabolic improvements: GLP-1 improves post-meal insulin secretion and lowers glucagon, which improves glycemia and can reduce metabolic drivers of weight gain
Specific medications recorded included antidepressant, antidiabetic (see below), and antihypertensive medications
US$ 20.54
US$ 24.71
US$ 25.25
US$ 26.09
US$ 27.78
US$ 20.56
US$ 28.18
